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Novel oligo(ethylene glycol)-based thermosensitive microgels with well engineered core-shell structures
were developed for storage and delivery of chemotherapeutic agents. The core is consisted of hydro-
phobic poly[2-(2-methoxyethoxy)ethyl methacrylate], while the shell is consisted of hydrophilic
copolymer of 2-(2-methoxyethoxy)ethyl methacrylate with oligo(ethylene glycol) methyl ether meth-
acrylates. These core-shell microgels exhibit tunable volume phase transition temperature and excellent
colloidal stability across the physiologically important temperature range. The thickness of the hydro-
philic shell can control the collapsing degree (or mesh size) of the hydrophobic core network, which can
be utilized to significantly increase the loading capacity of the model hydrophobic drugs dipyridamole by
tailoring the shell thickness of microgels. While the microgels are nontoxic, the drug molecules released
from the microgels remain active to kill the cancer cells. The presented results provide important
guidelines for the rational design of core-shell structured polymeric microgels for drug uptake and
release applications.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Microgel particles as drug delivery carriers for biological and
biomedical applications have received increasing attention during
the last decade due to their unique chemical and physical versatility
[1e6]. Microgels offer several advantages over other polymer based
drug delivery systems: simple synthesis, tunable size from nano-
meters to micrometers, large surface area for effective bio-
conjugation to add target ligands for site-specific delivery, an
interior network structure for the incorporation of drug molecules
to protect the drug from hydrolysis and other type of chemical
degradation, and potential biocompatibility. Among the various
approaches used to enhance the efficacy of chemotherapy is the use
of smart carrier systems that can release a drug in response to
stimuli, such as changes in pH, temperature, light, or the presence
of specific enzymes that are selectively encountered in relevant cell
organelles [7e10].
So far, the thermo-responsive poly(N-isopropylacrylamide)
(PNIPAM)-based microgels have been most extensively studied for
applications in drug delivery [8e21], including the introduction of
other environmental sensitivities such as pH, glucose, and light
sensitive components into the PNIPAM microgels to control the: þ1 718 982 3910.
u).
All rights reserved.drug release. However, the well studied PNIPAM-based microgels
have not been translated into a biomedical breakthrough although
a recent study on the microgels containing NIPAM and acrylic acid
(AA) indicated no adverse effects [16]. To meet the general
requirement in biocompatibility of the materials used for drug
delivery systems, an important challenge is to develop biocom-
patible polymers which have similar properties to PNIPAM [4].
Thermo-responsive polymers containing short oligo(ethylene
glycol) side chains were recently proposed as an attractive alter-
native to PNIPAM [22e28]. The lower critical solution temperature
(LCST) of these graft polymers are tunable through the control in
the compositions of the oligo(ethylene glycol) side chains. Lutz
et al. have reported that the LCST of the copolymers composed of
2-(2-methoxyethoxy)ethyl methacrylate (MEO2MA) with oligo
(ethylene glycol) methyl ether methacrylate (Mn ¼ 475 g/mol,
MEO9MA) can be adjusted by varying the comonomer ratios
[22e24]. Ishizone et al. found that the LCST of the poly[oligo
(ethylene glycol) alkyl ether methacrylates] is tunable by varying
the oligo(ethylene glycol) side chain length [26,27]. The longer the
oligo(ethylene glycol) side chain, the higher the LCST of the graft
polymer. In addition, the star-block copolymers of these oligo
(ethylene glycol) methyl ether methacrylate with star poly
(ethylene glycol) (PEG) exhibit thermoreversible sol-gel transitions
in physiological media [28]. Although the graft structure composed
of a carbonecarbon backbone and multiple oligo(ethylene glycol)
side chains is different from the standard linear PEG, these
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glycol) segments and are, in most cases, water-soluble and
biocompatible [25]. Hence, these thermosensitive nonlinear PEG
analogue polymers are very promising for biomedical applications.
Based on the free radical precipitation polymerization technique
used to synthesize PNIPAM microgels, Hu’s group has successfully
synthesized monodisperse copolymer microgels from the como-
nomers of MEO2MA and MEO9MA at different ratios [29]. With the
same two-step polymerization method used for the preparation of
PNIPAM-based core-shell microgels, they also successfully
synthesized core-shell microgels with the poly[oligo(ethylene
glycol) ethyl ethermethacrylate (Mn¼ 246 g/mol, EEO3MA)] as core
and the copolymer of EEO3MA, MEO5MA (Mn ¼ 300 g/mol) and
acrylic acid as shell. Similar to PNIPAM microgels, these nonlinear
PEG analogue polymer microgels can self-assemble into interesting
colloidal crystalline phases, depending on the concentration and
temperature [30].
The aim of this work is to develop a series of monodisperse oligo
(ethylene glycol)-based temperature sensitive core-shell microgels
with different shell thickness, and study their potential application
as delivery vehicles of hydrophobic drugs. The structures and
volume phase transitions of PNIPAM-based core-shell microgels
have been well studied [31e34]. The core-shell microgels can
provide unique internal structures andmulti-responsive properties
due to the mutual influence of core and shell swelling, which
enables us to explore the possibility to control the uptake and
release of drug molecules in the microgels. In our design, the poly
[2-(2-methoxyethoxy)ethyl methacrylate] [P(MEO2MA)] microgels
with a VPTT w22 C is used as a hydrophobic core and the cross-
linked copolymer of P(MEO2MA-co-MEO5MA) with the como-
nomer ratio of MEO2MA:MEO5MA ¼ 1:2 and a VPTT of w55 C is
used as a hydrophilic shell. In addition to the good biocompatibility,
the hydrophilic P(MEO2MA-co-MEO5MA) shell can influence the
core swelling. Although the free P(MEO2MA) core chain network is
hydrophobic and collapsed at temperature above its VPTT, the
addition of hydrophilic shell can mechanically expand the
collapsed core. As the shell thickness increases to certain extent,
the hydrophobic core network can be almost fully expanded even
at temperature above the VPTTof core microgels [33,34]. We expect
that the hydrophobic core with an open network structure should
load hydrophobic drug molecules much more effectively compared
to the collapsed structure. To demonstrate this conception,
a hydrophobic drug dipyridamole (DIP) (see Scheme 1) was studied












Scheme 1. Chemical structure of model drug DIP.the drug loading efficiency were investigated. The sustained drug
release behavior and cytotoxicity of the drug-free/drug-loaded
microgels were evaluated. The results presented in this work
provide important guidelines for the rational design of biocom-




All reagents were purchased from SigmaeAldrich. 2-(2-
methoxyethoxy)ethyl methacrylate (MEO2MA, 95%), oligo(ethylene
glycol)methyl ether methacrylate (Mn ¼ 300 g/mol, MEO5MA), and
poly(ethylene glycol) dimethacrylate (PEGDMA, Mn z 550 g/mol,
crosslinker) were purified with neutral Al2O3. Dipyridamole (DIP),
sodium dodecyl sulfate (SDS) and ammonium persulfate (APS)
were used as received.
2.2. Synthesis of oligo(ethylene glycol)-based core-shell microgels
The P(MEO2MA) core microgels were respectively synthesized
according to the compositions listed in Table 1. Typically, the
monomers, PEGDMA crosslinker, and SDS (5.0  105 mol) were
dissolved in 200 mL deionized water. The mixture was heated to 70
C under a N2 purge. After 1 h, APS (3.0  104 mol) was added to
the solution to initiate the polymerization. The reaction was
allowed to proceed for 5 h. The obtained core microgels were
purified by centrifugation (Thermo Electron Co. SORVALL RC-6
PLUS superspeed centrifuge), decantation, and redispersion in
deionized water for three cycles to remove the unreacted small
molecules and SDS surfactant molecules. The size of the core
microgels is controllable by varying the amount of SDS.
The P(MEO2MA-co-MEO5MA) shell was synthesized using core
microgel particles as nuclei for subsequent precipitation polymer-
ization. The shell precursors of MEO2MA and MEO5MA monomer
mixture in 1:2 M ratio, PEGDMA crosslinker, and SDS were
dissolved in deionized water (for details see Table 1), then the core
microgels were added. The mixture was heated to 70 C under a N2
purge. After 1 h, the APS initiator was added to start the polymer-
ization. The synthesis was allowed to proceed for 5 h. The resulted
core-shell microgels were purified with centrifugation/redis-
persion in water for three cycles, followed by 3 days of dialysis
(Spectra/Por molecularporous membrane tubing, cutoff
12000e14000) against very frequently changed water at room
temperature (w22 C).
2.3. Drug uptake experiments
8 mL DIP solution (0.5 mg/mL, pH ¼ 2.0) was added into the
10 mL microgel suspensions at a core microgel concentration of
1.0 mg/mL, resulting in a final pH around 3. After being stirred for
20 min, the pH of the mixture was adjusted to 8.0 by an addition ofTable 1
Feeding compositions for synthesis of the core-shell microgels.
Sample Core Solution (mol) Shell Solution (mol)
MEO2MA PEGDMA (550) MEO2MA MEO5MA PEGDMA (550)
Core microgel 0.0008 0.8  105
Shell microgel 0.001 0.002 0.3  104
CSM1 0.0008 0.8  105 0.001 0.002 0.3  104
CSM2 0.0008 0.8  105 0.002 0.004 0.6  104
CSM3 0.0008 0.8  105 0.004 0.008 1.2  104
CSM4 0.0008 0.8  105 0.008 0.016 2.4  104
Fig. 1. Size distributions of P(MEO2MA) core microgels synthesized with different SDS
concentrations, measured at 22 C and a scattering angle of q ¼ 45 .
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The DIPemicrogel complexes were then removed from suspension
by ultracentrifugation at 20,000 rpm and 22 C for 40 min and
redispersed in 10 mL of pH ¼ 8.0 NaOH solution. The supernatant
solution of residual DIP was collected and dissolved adequately
with 0.1 N HCl to form uniform solution with a final pH being
controlled at 3. The concentrations of the residual DIP were
determined by fluorescence emission intensity at 480 nmwith the
excitation wavelength of 414 nm [36e38], based on the linear
calibration curve with R2 > 0.99 measured using the DIP solutions
with known concentrations under the same condition. The exci-
tation at 414 nm gives an intensive emission band at 480 nm, which
allows the detection of DIP in the nanomolar range based on the
calibration curve. The drug loading efficiency of microgels was
calculated as follows:






2.4. In vitro drug release
The release of model drug from the microgel was evaluated by
the dialysis method [36,39]. The purified DIP-loaded microgel
dispersions (1 mL) were transferred into dialysis tubes with
amolecular weight cutoff of 12000e14000 and then immersed into
100 mL 0.005 M phosphate buffer solutions at different pHs. The
aliquots outside of the dialysis bag were sampled at time intervals.
The released drug concentrations were assayed using the fluores-
cence spectrometry for DIP, as outlined for the drug uptake
measurements. Cumulative release is expressed as the total
percentage of drug released through the dialysis membrane
over time.
2.5. In vitro cytotoxicity
Mouse melanoma cells B16F10 (2000 cell/well) were cultured in
DMEM containing 10% FBS and 1% penicillinestreptomycin in
a 96-well plate, and exposed to free DIP, DIP-free microgels, and
DIP-loaded microgels. To cover the high concentrations, the
microgels were concentrated and adjusted to an appropriate
concentration in DMEM right before feeding into thewell. The plate
was incubated at 37 C for 2 h. Themediumwas then aspirated, and
these wells were washed using fresh serum-free DMEM. After that,
25 mL of 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium
bromide (MTT) solution (5 mg/mL in PBS) were added to the wells.
After incubation for 2 h, the solution was aspirated and 100 mL of
DMSOwas added to each well to dissolve the formazan crystal, and
the plate was sealed and incubated overnight at 37 C with gentle
mixing. Cell viability was measured using a microplate reader at
570 nm. Positive controls contained no drug or microgels, and
negative controls contained MTT. Results are expressed as
a percentage of the absorbance of the positive control.
2.6. Characterization
The morphology of the core-shell microgels was characterized
with transmission electron microscopy (TEM). The TEM images
were taken on a Zeiss EM 902 transmission electron microscope
operating at an accelerating voltage of 100 kV. Approximately 10 mL
of the diluted microgel suspension was dropped on a Formvar-
covered copper grid (300 meshes) and then air-dried at room
temperature for the TEM measurements. The PL spectra were
obtained on a JOBIN YVON Co. FluoroMax-3 Spectrofluorometerequipped with a Hamamatsu R928P photomultiplier tube, cali-
brated photodiode for excitation reference correction from 200 to
980 nm. The pH values were obtained on a METTLER TOLEDO
SevenEasy pH meter.
The size and size distribution of the microgels under different
conditions were measured using a standard light scattering spec-
trometer (BI-200SM) equipped with a BI-9000 AT digital time
correlator (Brookhaven Instrument, Inc.). A HeeNe laser (35 mW,
633 nm) was used as the light source. The diluted microgel
dispersion solutions were passed through 0.45 mm Millipore
Millex-HV filters to remove dust. In dynamic light scattering, the
Laplace inversion of each measured intensityeintensity time
correlated function can result in a characteristic line width distri-
bution G(G) [35]. For a purely diffusive relaxation, G is related to the
translational diffusion coefficient D by (G/q2)C/0,q/0 ¼ D, where
q ¼ (4pn/l) sin(q/2) with n, l, and q being the solvent refractive
index, the wavelength of the incident light in vacuo, and
the scattering angle, respectively. G(G) can be further converted to
a hydrodynamic radius (Rh) distribution by using the
StokeseEinstein equation, Rh ¼ (kBT/6ph)D1, where T, kB, and h are
the absolute temperature, the Boltzmann constant, and the solvent
viscosity, respectively.3. Results and discussion
3.1. Synthesis of oligo(ethylene glycol)-based core-shell microgels
Our strategy to prepare the oligo(ethylene glycol)-based core-
shell microgels involves the first synthesis of a P(MEO2MA) core
microgel, followed by the synthesis of P(MEO2MA-co-MEO5MA) gel
layer on the core microgel. The P(MEO2MA) core microgels were
synthesized at 70 C (well above the LCST of P(MEO2MA)) based on
the well-established precipitation polymerization method. Fig. 1
shows the size distributions of the P(MEO2MA) microgels, in
terms of the hydrodynamic radius (Rh) measured at T ¼ 25 C and
q ¼ 45, synthesized with different concentrations of SDS surfac-
tant. All the obtained P(MEO2MA) microgel particles have a very
narrow size distribution. The DLS characterization indicated that
the obtained microgels are nearly monodispersed with a poly-
dispersity index of m2/<G>2 ¼ 0.001. The particle size decreases
with the increase in SDS concentration, which enables us to control
Fig. 2. Typical TEM image of the core-shell microgels (CSM3). The citric acid-capped
gold nanoparticles are attached onto the shell surface for easy visualization of the core-
shell structure. The scale bar is 1 mm.
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surfactant as the application needs. For the P(MEO2MA) core
microgels, the hydrodynamic diameter below 100 nm can be easily
obtained in the presence of small amount of SDS (e.g.,1e2mM,well
below the critical micelle concentration of SDS). The P(MEO2MA)
microgels with Rh ¼ 110 nm at 22 C was chosen as core model for
the further synthesis of core-shell microgels using the method
developed by Lyon’s group [31].
The further synthesis of P(MEO2MA-co-MEO5MA) gel shell was
performed at 70 C, at which the P(MEO2MA) core microgels are
fully collapsed. The collapsed core cannot only serve as nuclei for
further polymerization of shell, resulting in preferential growth of
the existing particles over the nucleation of new ones, but also
prevent the penetration of shell polymer into the core area [31a].
Fig. 2 shows the typical TEM image of dried core-shell microgels
CSM3 (see Table 1). The resulted core-shell microgels have a clear
boundary between the core and shell. The core-shell structure can
be clearly observed with a dark condensed core and a light contrast
shell. The low contrast of shell is due to the highly swollen state of
the P(MEO2MA-co-MEO5MA) gel layer at sample preparation
temperature. To observe the low contrast shell, the microgel
suspension was mixed with citric acid-capped gold nanoparticles
(w33 nm). The gold nanoparticles can be readily anchored onto theFig. 3. (A) Average Rh values of P(MEO2MA) core and P(MEO2MA-co-MEO5MA) shell micro
dependence of average Rh values of core-shell microgels with different shell thickness, respsurface of microgels through the hydrogen bonding between
theeCOOH groups and the ethylene oxide (EO) units. It is clear that
the gold nanoparticles anchored on the shell region give us an easy
visualization of the whole core-shell microgel particles. On the
basis of the core-shell structure as demonstrated, the thickness of
shell can be controlled by adding different amount of shell mono-
mers relative to a fixed amount of core particles. This is similar to
the synthesis of PNIPAM-based core-shell microgels [33].
3.2. Temperature-responsive volume phase transitions of the
core-shell microgels
Fig. 3A shows the thermo-responsive volume phase transitions
of the core microgels of P(MEO2MA) and the pure shell-composed
microgels of P(MEO2MA-co-MEO5MA), respectively. The volume
phase transition of core microgels begins around 13 C. The core
microgels are nearly collapsed at room temperature, and
completely collapsed at body temperature. In contrast, the shell-
composed P(MEO2MA-co-MEO5MA) microgels show a very broad
transition temperature beginning at around 40 C. However, at the
experimental temperature limit of w55 C, the shell-composed
microgels still have not reached the collapsing limit. Thus, the shell-
composed microgels are highly swollen and very hydrophilic at the
temperatures below 40 C.
Fig. 3B shows the temperature-dependent average Rh of the four
core-shell microgels. Two features should be noted. Firstly, the
increase in the feeding amount of shell components increases
the thickness of the resultant shells. The size difference between
the core-shell microgels and the parent core microgels can be
attributed to the shell layer. Thus the thickness of the shell was
estimated for the core-shell microgels. For example, at 7.5 C, the
increase of Rh from 157 nm for the core microgel to 165 nm (CSM1),
176 nm (CSM2), 190 nm (CSM3) and 256 nm (CSM4), respectively,
corresponds to a shell thickness of 8 nm, 19 nm, 33 nm, and 99 nm.
Secondly, the core-shell microgels with different shell thickness
exhibited different volume phase transition temperatures (VPTT).
The increase in shell thickness shifts the VPTT of the core microgels
toward higher temperatures, which is consistent with the results
observed in the PNIPAM-based core-shell microgels [31e33]. For
CSM1 and CSM2 with thinnest shells, these microgels start to
shrink at temperature above 15 C, which is slightly higher than the
VPTTof the core microgels. When the shell thickness is increased to
33 nm, the CSM3 microgels begins to shrink around 24 C, indi-
cating a shift of the VPTT of core with 11 C higher compared to the
core microgels. For the CSM4microgels with the thickest shell of 99gels as a function of temperature, respectively, measured at q ¼ 45 . (B) Temperature
ectively, measured at q ¼ 45 . The parent core is shown for comparison.
Fig. 4. DIP loading efficiency of the core-shell microgels as a function of shell thick-
ness, measured at a fixed number concentration of microgel particles and 22 C.
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the experimental temperature range, indicating that the phase
behavior of the CSM4microgels is almost similar to that of the pure
shell-composed microgels of P(MEO2MA-co-MEO5MA), in terms
of VPTT.
In addition to the VPTT shift, the shell thickness can also
dramatically affect the collapsing degree of the core region in the
core-shell microgels. As temperature increased from 10 to 32 C,
the full collapse of the free core microgels resulted in a decrease of
83 nm in Rh, while the Rh of the CSM1, CSM2, CSM3, and CSM4 only
reduced 42, 28, 20, and 18 nm, respectively. Obviously, the shell
can significantly restrict the shrinking of the core at the elevated
temperature. The thicker the shell is, the less the collapsing degree
of core network has. It was known that the swelling behavior of
a core-shell microgel is not a simple addition of the individual core
and shell components. The mutual interaction between the shell
and the core has been studied for PNIPAM-based core-shell
microgels [31e33]. In our systems, at temperatures below the VPTT
(e.g., <40 C) of the core-shell microgels, the hydrophilic shell will
try to maintain its swollen state (Fig. 3A). Although water is a poor
solvent for the P(MEO2MA) core network chains at temperature
above 30 C, the thick and swollen P(MEO2MA-co-MEO5MA)
copolymer gel shell will mechanically pull up the lightly cross-
linked core network. The final equilibrium collapsing degree of the
core networks in the core-shell microgels depends on the coun-
terbalance of the expanding (hydrophilic shell) and retracting
forces (hydrophobic core). Under this consideration, it allows us to
control the collapsing degree (mesh size of network) of the
hydrophobic core simply by tailoring the thickness of the shell.
When modified with a P(MEO2MA-co-MEO5MA) gel shell of
sufficient thickness, it is expected that the hydrophobic P
(MEO2MA) core networks can be stretched up to nearly a full
expansion even at the high temperatures above the VPTT of the
core but below that of the shell-composed microgels, e.g., 40 C.
Indeed, the collapsing degree (Rh,40 C/Rh,10 C ¼ 0.84) of the CSM4
microgels with the thickest shell of 99 nm is nearly the same as
that (Rh,40 C/Rh,10 C ¼ 0.82) of pure shell-composed microgels,
which indicates that the core in CSM4 microgels has no contri-
bution to the size reduction of the CSM4 microgels in this specific
temperature range and the core is almost fully expanded. This
unique shell thickness-dependent collapsing degree of the
hydrophobic core in our core-shell microgels is a key parameter for
the storage and delivery of hydrophobic drugs, because the equi-
librium collapsing degree (or mesh size) influences the loading
capacity and drug diffusion coefficient.
3.3. Drug loading efficiency of the P(MEO2MA-co-MEO5MA)
core-shell microgels
The hydrophobic P(MEO2MA) core of our core-shell microgels
offer the capability for storage of hydrophobic drugs. DIP was
chosen as the model drug. DIP is a known platelet inhibitor, coro-
nary vasodilator [40] and a coactivator of antitumor compounds
[41,42]. As a poor soluble weak base with a reported pKa of 6.4, the
solubility of DIP can be significantly different in different digestive
fluids. For example, DIP dissolves readily in the stomach but
incompletely in the intestine. Therefore, an effective carrier for
such a drug is required.
Fig. 4 shows the effect of shell thickness on the drug loading
efficiency of the core-shell microgels measured at a constant
number concentration of microgel particles together a fixed feeding
concentration of drug and 22 C. It is clear that the loading effi-
ciency increases with the increase in shell thickness, and then
reaches a nearly plateau slope, which indicates that the loading
efficiency only increases slightly with the further increase in shellthickness after the shell thickness reaches a certain value. These
results imply that the shell may contribute very little to the overall
drug loading. Control experiment confirmed that the pure shell-
composed microgels of P(MEO2MA-co-MEO5MA) did show an
extremely low loading capacity of 8.5 mg DIP/g dry microgel.
Although the free P(MEO2MA) core microgels also demonstrate
a low drug loading efficiency with 20% for DIP (equivalent to 80.5
mg DIP/g dry microgel), which is still one order of magnitude
higher in loading capacity than the pure shell-composed microgels.
Therefore, the loading of DIP into the core-shell microgels mainly
depends on the hydrophobic interactions [36,43] between the drug
and the P(MEO2MA) core.
Upon demonstrating the important role of the hydrophobic
interactions in DIP loading, it is noteworthy that the free P
(MEO2MA) core microgels, when compared with the core-shell
microgels, still exhibit low loading efficiency. We speculate that the
collapsing degree (mesh size of network) of the hydrophobic core is
another important factor related to the drug loading capacity. The
low loading efficiency of the free core microgels could be attributed
to their fully collapsed structure. The core microgels is nearly
collapsed at 22 C and the P(MEO2MA) network chains are hydro-
phobic and densely sticked together. Such a collapsed structure has
limited space to hold the drug molecules. The core-shell structure
can increase the drug loading efficiency dramatically. As we have
discussed above (Fig. 3B), the hydrophilic and swollen shell layer
can restrict the collapsing of the P(MEO2MA) core. Although the P
(MEO2MA) core network chains are still very hydrophobic, but the
swollen shell will pull up and stretch the core network. In such
a case, the hydrophobic core has open network with large mesh
size for drug molecules diffusing into the core area. The thicker
swollen shell has larger pulling force to prevent the collapsing of
the hydrophobic core network chains, thus the mesh size of the
core in CSM2 and CSM3 is larger than those of CSM1 and parent
core at 22 C, which can hold more hydrophobic drug molecules in
the interior of the hydrophobic core. When the shell thickness is
increased to a certain value, the mesh size of the hydrophobic core
network chains will no longer increase due to the limitation of
chemical crosslinking, thus the loading capacity of the core can
reach to a maximum and the overall loading efficiency of the core-
shell microgels can only increase very slightly with further increase
in shell thickness due to the very low loading capacity of shell
(Fig. 4). Therefore, certain shell thickness in the core-shell micro-
gels is necessary to achieve maximum drug loading.
Fig. 6. Cumulative DIP release from the core-shell microgels (CSM2) to buffer solutions
at different pH values and 22 C.
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effect on the drug loading efficiency. Fig. 5 shows the DIP loading
efficiency of the CSM2 and CSM3 core-shell microgels at different
temperatures. At the temperature window of between the VPTT of
the core microgels and the shell-composed microgels (e.g. 22e40
C, Figs. 3A and 5), the hydrophilic shell restricts the collapse of core
network chains, which can maintain the mesh size of hydrophobic
core to hold hydrophobic drug molecules. As a consequence, the
loading efficiency for drug molecules remains nearly a constant.
When the temperature is further increased (>40 C), the shell will
continuously shrink and gradually becomes hydrophobic, thus both
hydrophobic core and partial hydrophobic shell layer can hold
hydrophobic drug molecules, and a higher loading efficiency can be
expected. However, when temperature is increased to w65 C,
a dramatic decrease in drug loading efficiency was observed.
Although both core and shell are very hydrophobic to interact with
hydrophobic drug molecules, the shell is collapsed and loses its
function for pulling up the network at such a high temperature,
resulting in a collapsed P(MEO2MA) core without the restriction of
swollen shell. The very small mesh size of both core and shell gel
limits the loading amount of drug molecules. Clearly, in addition to
the drugepolymer hydrophobic interactions, the mesh size of the
hydrophobic core is also very important to determine the loading
capacity of hydrophobic drugs. These results indicate that the
temperature range between the VPTT of core microgels and the
shell-composed microgels is the most suitable condition to achieve
high loading efficiency of hydrophobic drugs.
3.4. In vitro release studies
Fig. 6 shows the cumulative release profiles of DIP from the
CSM2 core-shell microgels to buffer solutions at different pH values
and 22 C. It was anticipated that the drug molecules trapped in the
hydrophobic core could gradually diffuse into the hydrophilic shell
and then diffuse out of the shell to be released. At pH ¼ 7.4, only
w14% of the loaded DIP can be released after 28 h. When the pH
was decreased to 3,w35% of the loaded DIP can be released after 25
h due to the partial protonation of DIP. The results were further
analyzed to understand the release mechanism of the drug release
from the core-shell microgels. The analysis was performed on the
basis of the empirical equation proposed by Peppas et al. [44]:
Mt=MN ¼ ktnFig. 5. The temperature dependence of the DIP loading efficiency of the core-shell
microgels CSM2 and CSM3.where Mt and MN is the amount of drug released up to any time t
and the final amount of drug; k is a structural/geometric constant
and n is a release exponent related to the intimate mechanism of
release. The power law is easy to use and can be applied to most
diffusion-controlled release systems, even if it is too simple to offer
a robust prediction for complicated release phenomena. The
advantage of this approach is that it yields a convenient measure of
the constancy of release rate in the value of n. It also provides
a quick way to check the releasing mechanisms, as values of
n < 0.43 or n > 0.85 for spheres or sphere-like device indicate
another controlling process in addition to the diffusion process.
The n values presented in Fig. 6 are obtained from the best
fitting of our experimental curves. DIP is soluble at pH ¼ 3.0,
but the unionized DIP molecules have a very low water solubility
(5  106 g/mL) at pH ¼ 7.4 [45,46]. Despite of the difference in
the solubility of DIP, the exponent n was found to be nearly the
same at the two-pH values. The low n values exclude the simple
diffusion-controlled delivery mechanism. The investigated pH
variable affects the release rate, but essentially does not change the
drug release mechanism. These results confirm that the release of
DIP molecules trapped in the core-shell microgels obeys to two
correlated processes within the delivery matrix. One is related to
the interactions between the drug and polymer chains, including
the hydrophobic associations between DIP molecules and the
hydrophobic backbone chains as well as the hydrogen bonding
between the hydroxyl groups of the DIP molecules and the ether
oxygen of the ethylene glycol units. Another is a diffusion-
controlled step. It should be noted that the prepared microgels are
very stable. The drug loading/releasing test for aweek has nearly no
effect on the thermo-responsive volume phase transitions of the
core-shell microgels within the experimental errors (see
Supporting information), which indicates that the degradation
occurred on the drug carriers should be negligible during the drug
release time.3.5. In vitro cytotoxicity
For future biological applications, materials should be non- or
low-cytotoxic. To evaluate the cytotoxicity of the core-shell
microgels, in vitro cytotoxicity tests were conducted against mouse
melanoma B16F10 cells. As shown in Fig. 7, the empty core-shell
Fig. 7. (A) In vitro cytotoxicity of empty CSM3 microgels, and DIP-loaded microgels against B16F10 cells. (B) The control experiment on the free DIP solution was presented for
comparison. The concentrations of DIP used for the control study are equal to DIP-loaded in the interior of the CSM3 microgels correspondingly.
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upto 25.8 mg/mL. These results indicate that our microgels based on
the oligo-(ethylene glycol) macromonomers exhibit an excellent
in vitro biocompatibility. In contrast, when the cells were exposed
to DIP, the cell viability drastically decreased. Likewise, an even
higher cell death was observed in cells treated with DIP-loaded
microgels (containing equivalent amount of DIP to free DIP). When
the cells were incubated with DIP-loaded microgels even at
a concentration as low as 6.44 mg/mL (equivalent to about 0.17 mg/
mL free DIP), the cell viability drastically decreased, which indicates
that the DIP-loaded microgels can interact with cells and are
pharmacologically active. DIP is a known coactivator of antitumor
compounds, and the formation of metastatic tumors could be
inhibited by such inhibitors of platelet aggregation [41]. Despite of
these encouraging preliminary results and a compelling biochem-
ical rationale, we cannot conclude whether the DIP drug would be
pharmacologically active for cancer treatment because very limited
information exists on the clinical use of anticoagulants for the
prevention or treatment of cancer [42]. Nevertheless, the increase
in cytotoxicity in the presence of DIP-loaded microgels can be
attributed to the cellular uptake of DIP-loaded microgels and
possibly their sustained-release property.4. Conclusion
Well-defined oligo(ethylene glycol)-based doubly thermo-
sensitive core-shell microgels with the P(MEO2MA) microgel as
a hydrophobic core and the P(MEO2MA-co-MEO5MA) gel layer as
a hydrophilic shell could be successfully synthesized via precipi-
tation polymerization. The presence of P(MEO2MA-co-MEO5MA)
hydrophilic shell could prevent the hydrophobic core network from
collapsing, resulting in a shift of the VPTT of P(MEO2MA) core to
higher temperatures in comparison with the free parent core
microgels. The simple synthesis also allows us to tailor the shell
layer to different thickness. When the shell thickness is increased to
a certain extent (e.g., 50 nm), the hydrophobic core network can
be fully expanded. This unique structure of hydrophobic core with
the open network (or large mesh size) in the core-shell microgels
can dramatically improve the loading capacity for hydrophobic
drugs, which indicates that both the drug-core hydrophobic inter-
actions and the mesh size of core networks are important to
determine the drug loading efficiency. These nontoxic core-shell
microgels provide well-controlled drug loading yield and sustained
drug release profiles. The DIP-loaded core-shell microgels signifi-
cantly enhanced the in vitro cytotoxicity against tumor cells in
comparison with the equivalent amount of free DIP molecules insolution. Although DIP was selected as a specific model drug in this
study, the concept and technique of developing nontoxic polymeric
drug carriers by loading drug molecules into polymer chain
networks through stimuli-responsive gel engineering can be
generalized to delivermany other types of therapeutic or diagnostic
agents.
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